MLYS Quote, Financials, Valuation and Earnings

Checkpoint Therapeutics has a net margin of -- compared to Mineralys Therapeutics's net margin of -16268.29%. Mineralys Therapeutics's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

Mineralys Therapeutics has a consensus price target of $38.29, signalling upside risk potential of 136.77%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 7%. Given that Mineralys Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Mineralys Therapeutics is more attractive than Checkpoint Therapeutics.

Mineralys Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.242%.

Mineralys Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics pays -- of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Mineralys Therapeutics quarterly revenues are --, which are smaller than Checkpoint Therapeutics quarterly revenues of $41K. Mineralys Therapeutics's net income of -$48.9M is lower than Checkpoint Therapeutics's net income of -$9.7M. Notably, Mineralys Therapeutics's price-to-earnings ratio is -- while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics is -- versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of -- compared to Mineralys Therapeutics's net margin of -53.33%. Mineralys Therapeutics's return on equity of -- beat Geron's return on equity of -59.29%.

Mineralys Therapeutics has a consensus price target of $38.29, signalling upside risk potential of 136.77%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 157.14%. Given that Geron has higher upside potential than Mineralys Therapeutics, analysts believe Geron is more attractive than Mineralys Therapeutics.

Mineralys Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron has a beta of 0.535, suggesting its less volatile than the S&P 500 by 46.549%.

Mineralys Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Mineralys Therapeutics quarterly revenues are --, which are smaller than Geron quarterly revenues of $47.5M. Mineralys Therapeutics's net income of -$48.9M is lower than Geron's net income of -$25.4M. Notably, Mineralys Therapeutics's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics is -- versus 14.68x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics has a net margin of -- compared to Mineralys Therapeutics's net margin of 77.17%. Mineralys Therapeutics's return on equity of -- beat Protagonist Therapeutics's return on equity of 52.01%.

Mineralys Therapeutics has a consensus price target of $38.29, signalling upside risk potential of 136.77%. On the other hand Protagonist Therapeutics has an analysts' consensus of $69.10 which suggests that it could grow by 31.54%. Given that Mineralys Therapeutics has higher upside potential than Protagonist Therapeutics, analysts believe Mineralys Therapeutics is more attractive than Protagonist Therapeutics.

Mineralys Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protagonist Therapeutics has a beta of 2.340, suggesting its more volatile than the S&P 500 by 134.022%.

Mineralys Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics pays -- of its earnings as a dividend. Protagonist Therapeutics pays out -- of its earnings as a dividend.

Mineralys Therapeutics quarterly revenues are --, which are smaller than Protagonist Therapeutics quarterly revenues of $170.6M. Mineralys Therapeutics's net income of -$48.9M is lower than Protagonist Therapeutics's net income of $131.7M. Notably, Mineralys Therapeutics's price-to-earnings ratio is -- while Protagonist Therapeutics's PE ratio is 12.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics is -- versus 7.65x for Protagonist Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Alpha Teknova has a net margin of -- compared to Mineralys Therapeutics's net margin of -61.73%. Mineralys Therapeutics's return on equity of -- beat Alpha Teknova's return on equity of -31.69%.

Mineralys Therapeutics has a consensus price target of $38.29, signalling upside risk potential of 136.77%. On the other hand Alpha Teknova has an analysts' consensus of $10.67 which suggests that it could grow by 72.69%. Given that Mineralys Therapeutics has higher upside potential than Alpha Teknova, analysts believe Mineralys Therapeutics is more attractive than Alpha Teknova.

Mineralys Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alpha Teknova has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mineralys Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics pays -- of its earnings as a dividend. Alpha Teknova pays out -- of its earnings as a dividend.

Mineralys Therapeutics quarterly revenues are --, which are smaller than Alpha Teknova quarterly revenues of $9.3M. Mineralys Therapeutics's net income of -$48.9M is lower than Alpha Teknova's net income of -$5.7M. Notably, Mineralys Therapeutics's price-to-earnings ratio is -- while Alpha Teknova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics is -- versus 7.89x for Alpha Teknova. Usually stocks with elevated PS ratios are considered overvalued.